Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xervyteg + ipilimumab + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Rectal
01
Overview
Xervyteg + ipilimumab + nivolumab is an investigational combination regimen consisting of Xervyteg (MaaT013), a donor-derived, standardized, high-diversity microbiome ecosystem therapy, and the immune checkpoint inhibitors ipilimumab (an anti-CTLA-4 monoclonal antibody) and nivolumab (an anti-PD-1 monoclonal antibody). Developed in collaboration with Assistance Publique - Hôpitaux de Paris (AP-HP), INRAE, and Gustave Roussy, this combination is being evaluated in the Phase 2a PICASSO clinical trial for the treatment of patients with advanced, unresectable, or metastatic melanoma who are immunotherapy-naïve. The regimen aims to leverage the gut microbiome to modulate the immune system, enhance the efficacy of dual checkpoint inhibition, and potentially improve patient tolerability and response rates.
- Other names
- MaaT013 + ipilimumab + nivolumabMaaT013 + nivolumab + ipilimumabXervyteg + ipilimumab + nivolumabXervyteg + nivolumab + ipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Xervyteg + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xervyteg + ipilimumab + nivolumab.